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ABSTRACT 
Quality control of pharmaceutical product emphasizes on various testing of the product which 
include both in-process and finished product quality control tests that are conducted prior to 
release of the drug in the market. In the present study the quality control parameters of ten 
different brands of Montelukast tablets available in Bangladesh were evaluated and compared to 
assess the quality of the tablets. The samples of the tablets were taken from five leading 
pharmaceutical companies of Bangladesh represented as A to E respectively, three medium 
ranked companies designated as F, G, H and two low ranked companies denoted as I and J 
respectively. Quality control tests such as weight variation, friability, hardness as well as 
disintegration tests were performed. In vitro dissolution study was carried out and analyzed by 
HPLC to determine the percentage release of drug after 30 minutes which may reflect in vivo 
performance of the drug. The weight variation results show that there was hardly any variation 
among the leading pharmaceutical companies (value ranging 0.17±0.01 gm to 0.2±0.01 gm) 
except for company B (0.35±0.01 gm) and the middle and lower ranked company showed 
slightly higher results. The tablets of all the ten companies showed acceptable values of hardness 
except for one low-ranked company J with a high value of 16.57±1.4 kg/cm2. There is a marginal 
difference in the result of the friability test of the all the ten companies (all values less than 1% 
according to BP specification), signifying that the Montelukast tablets produced by the different 
companies of Bangladesh have sufficient mechanical strength to withstand the pressure due to 
processing, storage and shipment. Disintegration times of the tablets of leading companies were 
found to be within 3 minutes indicating a very good result except for company A (7.40±0.9 
minutes). Company F and company I showed the highest disintegration times (9.4±1.17 minutes 
and 9.8±3.6 minutes respectively). Consequently, the percentage release of drug for company A, 
company F and company I are less compared to other companies as shown by the dissolution 
study. Nevertheless, all the companies showed greater than 90% dissolution of drug after 30 
minutes, thus complying with the specifications of British Pharmacopeia and US FDA guidelines 
for INN drugs. Hence, it can be concluded that Montelukast tablets produced by the 
pharmaceutical companies in Bangladesh are of consistent quality with very little variation 
among them and complies with the specifications of British Pharmacopeia. 
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1. INTRODUCTION 
Montelukast is a leukotriene receptor antagonist (LTRA) used for the treatment of asthma and to 
relieve symptoms of seasonal allergies in children and adults (1-3). Leukotrienes are fatty 
compounds produced by the immune system which are responsible for asthma, bronchitis and 
constriction of airway (4). Leukotrienes constitute a group of locally acting hormones produced 
in living systems from arachidonic acid. Major leukotrienes are Leukotriene B4 (LTB4), 
Leukotriene C4 (LTC4), Leukotriene D4 (LTD4), and Leukotrine E4 (LTE4). Biosynthesis of 
these leukotrienes begins with the action of the enzyme 5-lipoxygenase on arachidonic acid to 
produce Leukotrine A4 (5). A leukotriene antagonist is any drug or substance that inhibit 
leukotrienes (6). A leukotriene antagonist is also known as leukast (6). Montelukast causes 
inhibition of airway cysteinyl leukotriene receptors by the inhibition of bronchoconstriction due 
to inhaled LTD4 in asthmatics (7). The structure of leukotrienes was elucidated in 1979 and their 
proposed implication in the etiology of respiratory diseases caused many laboratories to initiate 
programs to discover blockers of leukotrienes as new treatment for asthma. Merck Frost started 
two parallel programs, one to find an inhibitor of the key biosynthesizing enzyme 5-lipoxygenase 
and the other to find a selective blocker of the Leukotrine D4 receptor. These projects proceeded 
for more than 10 years with many failures and 6 compounds were brought into human clinical 
trials before Montelukast was identified (8). Montelukast received the UK license since 1998 as 
add-on therapy for the treatment of the patients 6 years or older with mild to moderate asthma 
who were inadequately controlled as required with short-acting ß-agonists and inhaled 
corticosteroids. It is also licensed for prophylaxis for asthma in which the predetermined 
component is exercise-induced bronchoconstriction. The license has recently been extended to 
include the 2 to 5 year age group (9). In August 3 2012, FDA has approved 10 generic drug 
manufacturers to start making generic versions of Singulair (Montelukast sodium). The available 
forms of Montelukast sodium in market are 10mg film-coated tablet and 5mg chewable tablet 
(10). Commonly available brand of Montelukast sodium is known as Singulair produced by 
Merck Sharpe & Dohme Ltd (11-12). Montelukast is highly bound to plasma protein and rapidly 
metabolized (13). The dose of the drug varies according to age, gender and clinical state of the 
person. Pregnant and person sensitive to Montelukast should avoid this drug (14). 
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1.1. AIM  
In the pharmaceutical industry, total quality of the product must be ensured in order to avoid the 
product which does not meet the requirements and specifications mentioned in the 
Pharmacopoeias (United States Pharmacopeia, British Pharmacopeia). When the production 
process is running there is a chance for errors to occur, so it is necessary to control the error that 
may occur during production procedure and stringent quality control tests must be performed to 
determine the quality of the product. Quality control of pharmaceutical product emphasizes on 
various testing of the product to find out the defects that may occur during production. Therefore 
to assure the total quality of the product, both in process and finished product quality control 
tests are essential requirements of the manufacturing process which are conducted prior to 
release of the drug in the market. In-process control tests are tests that are performed before the 
manufacturing process is completed in order to comply with the specifications.  
The aim of the study is to evaluate and compare the quality control parameters of oral 
Montelukast sodium tablets of top five leading pharmaceutical companies, three medium ranked 
pharmaceutical companies and two low ranked pharmaceutical companies marketed in 
Bangladesh in order to assess the quality and efficacy of oral Montelukast sodium tablets 
available in Bangladesh. 
The quality control tests performed during the study are as follows: 
(i) Weight variation test  
(ii)  Hardness test 
(iii) Friability test 
(iv) Disintegration test  
(v) Dissolution test using USP Paddle II method and analyzed by HPLC 
 
                                               Figure-1. Structure of Montelukast 
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Commonly used brand name(s) –Singulair 
Manufacturer –Merek Sharpe & Dohme Ltd. 
Chemical name – [R]-1-[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl] phenyl-3-[2-(1-hydroxy-1-
methylethyl) phenyl] propyl] thio] methyl] cyclopropaneacetic acid, monosodium salt.  
Category-antihistaminic (leukotriene receptor antagonist) (15) 
COMPANY NAME BRAND NAME DOSAGE FORM 
Square Pharmaceuticals Ltd MONTENE 10 Montelukast sodium INN 10mg/tablet 
Beximco Pharmaceuticals Ltd MONOCAST Montelukast sodium INN 10mg/tablet 
Incepta Pharmaceuticals Ltd MONTAIR Montelukast sodium INN 4mg, 5mg & 10mg/tablet 
Renata Ltd ODMON Montelukast sodium INN 5mg & 10mg/tablet 
Eskayef Bangladesh Ltd LUMONA 10 Montelukast sodium INN 10mg/tablet 
ACME Laboratories Ltd MONAS Montelukast sodium INN 4mg, 5mg & 10mg/tablet 
Opsonin Pharma Limited TRILOCK Montelukast sodium INN 4mg, 5mg & 10mg/tablet 
ACI Limited REVERSAIR Montelukast sodium INN 10mg/tablet 
Drug International Ltd M-KAST-10 Montelukast sodium INN 10mg/tablet 
Healthcare Pharmaceuticals 
Limited AERON 
Montelukast sodium INN 
10mg/tablet 
 
Table-1. Commercially available oral Montelukast sodium tablets in Bangladesh  
1.2. THERAPEUTIC INDICATIONS 
1.2.1. Asthma-Asthma is a common chronic inflammatory disease of the airways characterized 
by variable and recurring symptoms, reversible airflow obstruction and bronchospasm (6). 
Common symptoms include wheezing, coughing, chest tightness, and shortness of breath (2). 
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Montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults 
and pediatric patients 2 years of age and older (14). 
1.2.2. Exercise-Induced Bronchospasm- Exercise-induced bronchospasm is frequent in 
children and in young patients with mild asthma, and is often associated with other markers of 
uncontrolled asthma, such as symptoms induced by other nonspecific triggers or frequent 
exacerbations (16-17). In these cases, the patient should be managed according to general 
recommendations. Sometimes, however, bronchoconstriction is induced almost exclusively by 
exercise, particularly in elite athletes, thus representing a true clinical phenotype (18,19). In these 
patients, Montelukast has demonstrated greater efficacy than beta2-agonists, both as regular and 
occasional treatment, in preventing exercise-induced asthma, with the advantage of no loss of 
efficacy over time (20-22). 
Another trigger of asthma attacks is aspirin and other related chemicals (often present in some 
food as additives or preservatives). Aspirin-sensitive patients often have severe asthma, and may 
have-greater activation of the leukotriene cascade, as demonstrated by high levels of urinary 
LTE4 (23). Some studies tried to assess whether aspirin-sensitive patients are particularly 
responsive to LTRA treatment, with some positive results (24). However, these data have not 
been confirmed by other studies. 
1.2.3. Allergic Rhinitis- Allergic rhinitis is an allergic inflammatory reaction which occurs in 
nasal airway. It occurs when an allergen, such as pollen, dust, or animal dander (particles of shed 
skin and hair) is inhaled by an individual with a sensitized immune system (14). Allergic rhinitis 
is frequently associated with asthma both in allergic and nonallergic patients, and untreated 
upper airway disease represents a frequent cause of uncontrolled asthma (25). As Montelukast is 
effective on both upper and lower airways, its use might be particularly useful in patients with 
both asthma and rhinitis. A post hoc analysis of a subgroup of patients enrolled in a study 
comparing budesonide plus Montelukast with a doubling dose of budesonide showed that 
patients with asthma and rhinitis reported a greater improvement in symptoms and pulmonary 
function with budesonide plus Montelukast (26). After that, many other clinical and 
observational studies have confirmed that the addition of Montelukast to current treatment 
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induced a considerable and long-lasting improvement in asthma control in patients with both 
asthma and rhinitis (27-28).  
Montelukast sodium is indicated for the relief of symptoms of seasonal and perennial allergic 
rhinitis in patients 2 years of age and older (14). 
1.3. PHYSICAL PROPERTY 
1.3.1. Description- Montelukast sodium is a hygroscopic, optically active, white or off white 
powder (18). 
1.3.2. Solubility-Freely soluble in ethanol, methanol, water and in acetanilide it is partially 
insoluble (7). 
1.4. MECHANISM OF ACTION 
Montelukast is a selective leukotrine receptor antagonist of cysteinyl leukotriene CysLT1 
receptor. The cysteinyl leukotnienes (LTC4, LTD4, LTE4) are produced form arachidonic acid 
metabolism that are released form mast cell, eosinophils and other cells. Cysteinyl leukotriene 
receptors are found in human airway. Cysteinyl leukotriene binds with this receptor. This 
binding is associated with the pathophysiology of asthma, including smooth muscle construction, 
airway edema, and altered cellular activity (factor that helps in asthma) and that is how 
Montelukast inhibits broncoconstriction.  Montelukast inhibits physiologic action of LTD4 at the 
CysLT1 receptors without any agonist activity (7). 
1.5. PHARMACOKINETICS  
1.5.1. Absorption- Montelukast is rapidly absorbed following oral administration. After 
administration of the 10 mg film-coated tablet to fasted adults, the mean peak Montelukast 
plasma concentration (Cmax) is achieved in 3 to 4 hours (Tmax). The mean oral bioavailability 
is 64%. The oral bioavailability and Cmax are not influenced by a standard meal in the morning. 
For the 5 mg chewable tablet, the mean Cmax is achieved in 2 to 2.5 hours after administration 
to adults in the fasted state. The mean oral bioavailability is 73% in the fasted state versus 63% 
when administered with a standard meal in the morning. 
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For the 4 mg chewable tablet, the mean Cmax is achieved 2 hours after administration in 
pediatric patients 2 to 5 years of age in the fasted state. 
The 4 mg oral granule formulation is bioequivalent to the 4 mg chewable tablet when 
administered to adults in the fasted state. 
The safety and efficacy of Montelukast sodium in patients with asthma were demonstrated in 
clinical trials in which the 10 mg film-coated tablet and 5 mg chewable tablet formulations were 
administered in the evening without regard to the time of food ingestion. The safety of 
montelukast sodium in patients with asthma was also demonstrated in clinical trials in which the 
4 mg chewable tablet and 4 mg oral granule formulations were administered in the evening 
without regard to the time of food ingestion. The safety and efficacy of Montelukast sodium in 
patients with seasonal allergic rhinitis were demonstrated in clinical trials in which the 10 mg 
film-coated tablet was administered in the morning or evening without regard to the time of food 
ingestion. 
The comparative pharmacokinetics of Montelukast when administered as two 5 mg chewable 
tablets versus one 10 mg film-coated tablet has not been evaluated (7, 17). 
1.5.2. Distribution- Montelukast is more than 99% bound to plasma proteins. The steady state 
volume of distribution of Montelukast averages 8 to 11 liters. Studies in rats with radiolabeled 
Montelukast indicate minimal distribution across the blood-brain barrier. In addition, 
concentrations of radiolabeled material at 24 hours postdose were minimal in all other tissues (7, 
17). 
1.5.3. Metabolism- Montelukast is extensively metabolized. In studies with therapeutic doses, 
plasma concentrations of metabolites of Montelukast are undetectable at steady state in adults 
and pediatric patients (7, 16). 
In vitro studies using human liver microsomes indicate that CYP3A4, 2C8, and 2C9 are involved 
in the metabolism of Montelukast. At clinically relevant concentrations, 2C8 appears to play a 
major role in the metabolism of Montelukast (7, 17). 
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1.5.4. Elimination-The plasma clearance of Montelukast averages 45 mL/min in healthy adults. 
Following an oral dose of radiolabeled Montelukast, 86% of the radioactivity was recovered in 5 
day fecal collections and <0.2% was recovered in urine. Coupled with estimates of Montelukast 
oral bioavailability, this indicates that Montelukast and its metabolites are excreted almost 
exclusively via the bile (7, 18). 
In several studies, the mean plasma half-life of Montelukast ranged from 2.7 to 5.5 hours in 
healthy young adults. The pharmacokinetics of Montelukast are nearly linear for oral doses up to 
50 mg. During once-daily dosing with 10 mg Montelukast, there is little accumulation of the 
parent drug in plasma (14%). 
1.6. PHARMACODYNAMICS 
Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the 
ability to inhibit bronchoconstriction due to inhaled LTD4 in asthmatics. Dose as low as 5 mg 
cause substantial blockage of LTD4-induced bronchoconstriction. In a placebo-controlled, 
crossover study (n=12), Montelukast sodium inhibited early- and late-phase bronchoconstriction 
due to antigen challenge by 75% and 57%, respectively. 
The effect of Montelukast sodium on eosinophils in the peripheral blood was examined in 
clinical trials. In patients with asthma aged 2 years and older who received Montelukast sodium, 
a decrease in mean peripheral blood eosinophil counts ranging from 9% to 15% was noted, 
compared with placebo, over the double-blind treatment periods. In patients with seasonal 
allergic rhinitis aged 15 years and older who received Montelukast sodium, a mean increase of 
0.2% in peripheral blood eosinophil counts was noted, compared with a mean increase of 12.5% 
in placebo-treated patients, over the double-blind treatment periods; this reflects a mean 
difference of 12.3% in favor of Montelukast sodium. The relationship between these 
observations and the clinical benefits of Montelukast noted in the clinical trials is not known (7, 
14, 17). 
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1.7. DOSAGE AND ADMINISTRATION  
1.7.1. Asthma 
Montelukast sodium should be taken once daily in the evening. The following doses are 
recommended: 
For adults and adolescents 15 years of age and older: one 10-mg tablet. 
For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet. 
For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet. 
Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not 
been established. 
There have been no clinical trials in patients with asthma to evaluate the relative efficacy of 
morning versus evening dosing. The pharmacokinetics of Montelukast are similar whether dosed 
in the morning or evening. Efficacy has been demonstrated for asthma when Montelukast was 
administered in the evening without regard to time of food ingestion (14, 16). 
1.7.2. Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older 
For prevention of EIB, a single 10 mg dose of Montelukast should be taken at least 2 hours 
before exercise. An additional dose of Montelukast should not be taken within 24 hours of a 
previous dose. Patients already taking Montelukast sodium daily for another indication 
(including chronic asthma) should not take an additional dose to prevent EIB. All patients should 
have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger 
than 15 years of age have not been established. Daily administration of Montelukast sodium for 
the chronic treatment of asthma has not been established to prevent acute episodes of EIB (14, 
17). 
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1.7.3. Allergic Rhinitis 
For allergic rhinitis, Montelukast sodium should be taken once daily. Efficacy was demonstrated 
for seasonal allergic rhinitis when Montelukast was administered in the morning or the evening 
without regard to time of food ingestion. The time of administration may be individualized to 
suit patient needs. 
The following doses for the treatment of symptoms of seasonal allergic rhinitis are 
recommended: 
For adults and adolescents 15 years of age and older: one 10-mg tablet. 
For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet. 
For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet 
Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic 
rhinitis have not been established. 
The following doses for the treatment of symptoms of perennial allergic rhinitis are 
recommended: 
For adults and adolescents 15 years of age and older: one 10-mg tablet 
For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet 
For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet 
Safety and effectiveness in pediatric patients younger than 2 years of age with perennial allergic 
rhinitis have not been established (14). 
1.7.4. Asthma and Allergic Rhinitis 
Patients with both asthma and allergic rhinitis should take only one Montelukast sodium dose 
daily in the evening (14). 
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1.8. USE IN PREGNANCY 
1.8.1. Pregnancy Category B 
There are no adequate and well-controlled studies in pregnant women (7). 
1.8.2. Teratogenic Effect 
No teratogenicity was observed in rats and rabbits at doses approximately 100 and 110 times, 
respectively, the maximum recommended daily oral dose in adults based on AUCs. 
During worldwide marketing experience, congenital limb defects have been rarely reported in 
the offspring of women being treated with SINGULAIR during pregnancy. Most of these women 
were also taking other asthma medications during their pregnancy. A causal relationship between 
these events and SINGULAIR has not been established (14, 17). 
1.8.3. Nursing Mothers 
Studies in rats have shown that Montelukast is excreted in milk. It is not known if Montelukast is 
excreted in human milk. Because many drugs are excreted in human milk, caution should be 
exercised when SINGULAIR is given to a nursing mother (14). 
1.9. CONTRAINDICATIONS 
1.9.1. Acute Asthma 
Montelukast sodium is not indicated for use in the reversal of bronchospasm in acute asthma 
attacks, including status asthmaticus. Patients should be advised to have appropriate rescue 
medication available. Therapy with Montelukast sodium can be continued during acute 
exacerbations of asthma (19). Patients who have exacerbations of asthma after exercise should 
have available for rescue a short-acting inhaled β-agonist (14). 
 
 
24 
 
1.9.2. Concomitant Corticosteroid Use 
While the dose of inhaled corticosteroid may be reduced gradually under medical supervision, 
Montelukast sodium should not be abruptly substituted for inhaled or oral corticosteroids (14). 
1.9.3. Aspirin Sensitivity 
Patients with known aspirin sensitivity should continue avoidance of aspirin or non-steroidal 
anti-inflammatory agents while taking Montelukast sodium. Although Montelukast sodium is 
effective in improving airway function in asthmatics with documented aspirin sensitivity, it has 
not been shown to truncate bronchoconstrictor response to aspirin and other non-steroidal anti-
inflammatory drugs in aspirin-sensitive asthmatic patients (14). 
1.9.4. Neuropsychiatric Events 
Neuropsychiatric events have been reported in adult, adolescent, and pediatric patients taking 
Montelukast sodium. Post-marketing reports with Montelukast sodium use include agitation, 
aggressive behavior or hostility, anxiousness, depression, disorientation, disturbance in 
attention, dream abnormalities, hallucinations, insomnia, irritability, memory 
impairment, restlessness, somnambulism, suicidal thinking and behavior (including suicide), and 
tremor. The clinical details of some post-marketing reports involving Montelukast sodium appear 
consistent with a drug-induced effect. 
Patients and prescribers should be alert for neuropsychiatric events. Patients should be instructed 
to notify their prescriber if these changes occur. Prescribers should carefully evaluate the risks 
and benefits of continuing treatment with Montelukast sodium if such events occur (14). 
1.9.5. Eosinophilic Conditions 
Patients with asthma on therapy with Montelukast sodium may present with systemic 
eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-
Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These 
events usually, but not always, have been associated with the reduction of oral corticosteroid 
therapy. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary 
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symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal 
association between Montelukast sodium and these underlying conditions has not been 
established (14). 
1.9.6. Other precautions 
Before taking Montelukast, consulting with doctor or pharmacist is required if patients are 
allergic to it; or if they have any other allergies. This product may contain inactive ingredients, 
which can cause allergic reactions or other problems (14, 16). 
Before using this drug, patient should tell to doctor or pharmacist about his medical history, 
especially of: liver disease (14). 
Before having surgery, patients have to consult with doctor or dentist about all the products they 
use (including prescription drugs, nonprescription drugs, and herbal products) (14, 16, 17). 
The chewable tablets may contain aspartame. If the patients have phenylketonuria (PKU) or any 
other condition that requires him to limit/avoid aspartame (or phenylalanine) in his diet, he 
should ask doctor or pharmacist about using this medication safely (18). 
During pregnancy, this medication should be used only when clearly needed. Patient should 
discuss about the risks and benefits with his doctor (18). 
1.10. SIDE EFFECTS 
Serious side effects: 
¾ Skin rash, bruising, severe tingling, numbness, pain, muscle weakness; 
¾ Mood or behavior changes, anxiety, depression, suicidal tendency  
¾ Tremors or shaking; 
¾ Easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint 
spots under the skin; 
¾ Severe sinus pain, swelling, or irritation; or 
¾ Worsening asthma symptoms. 
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Less serious side effects may include: 
¾ headache; 
¾ stomach pain, heartburn, upset stomach, nausea, diarrhea; 
¾ tooth pain; 
¾ tired feeling; 
¾ fever, stuffy nose, sore throat, cough, hoarseness; or 
¾ mild rash (17) 
1.11. DRUG INTERACTIONS 
The Montelukast causes significant change in the pharmacokinetics of theophylline, warfarin, 
immunoreactive digoxin, terfenadine, fexofenadine, oral contraceptives containing norethindrone 
1mg and ethinyl esterdiol 35mcg, prednisone, or prednisolone. Combination containing any of 
the following medications, depending on the amount percent, may also interact with this 
medication. 
Phenobarbital (recent use results in significant decrease [approximately 40%] in bioavailability 
curve for montelukast, as a result of induction of hepatic metabolism; however no dosage 
adjustment is required (2). 
Montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state:  
¾ Did not cause clinically significant changes in the kinetics of a single intravenous dose of 
theophylline (predominantly a cytochrome P450 1A2 substrate).  
¾ Did not change the pharmacokinetic profile of warfarin (primarily a substrate of CYP 
2C9, 3A4 and 1A2) or influence the effect of a single 30-mg oral dose of warfarin on 
prothrombin time or the INR (International Normalized Ratio).  
¾ Did not change the pharmacokinetic profile or urinary excretion of immunoreactive 
digoxin.  
¾ Did not change the plasma concentration profile of terfenadine (a substrate of CYP 3A4) 
or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval 
following co-administration with terfenadine 60 mg twice daily.  
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Montelukast at doses of ≥100 mg daily dosed to pharmacokinetic steady state:  
¾ Did not significantly alter the plasma concentrations of either component of an oral 
contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg.  
¾ Did not cause any clinically significant change in plasma profiles of prednisone or 
prednisolone following administration of either oral prednisone or intravenous 
prednisolone (16). 
Thyroid Hormones, Sedative Hypnotics, Non-Steroidal Anti-Inflammatory Agents, 
Benzodiazepines, and Decongestants: Although additional specific interaction studies were not 
performed, Montelukast was used concomitantly with a wide range of commonly prescribed 
drugs in clinical studies without evidence of clinical adverse interactions. These medications 
included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, 
benzodiazepines, and decongestants. 
Cytochrome P450 (CYP) Enzyme Inducers: Phenobarbital, which induces hepatic metabolism, 
decreased the area under the plasma concentration curve (AUC) of Montelukast approximately 
40% following a single 10-mg dose of Montelukast. No dosage adjustment for Montelukast 
sodium is recommended. It is reasonable to employ appropriate clinical monitoring when potent 
CYP enzyme inducers, such as phenobarbital or rifampin, are co-administered with Montelukast 
sodium. 
Montelukast is a potent inhibitor of CYP2C8 in vitro. However, data from a clinical drug-drug 
interaction study involving Montelukast and rosiglitazone (a probe substrate representative of 
drugs primarily metabolized by CYP2C8) in 12 healthy individuals demonstrated that the 
pharmacokinetics of rosiglitazone are not altered when the drugs are coadministered, indicating 
that Montelukast does not inhibit CYP2C8 in vivo. Therefore, Montelukast is not anticipated to 
alter the metabolism of drugs metabolized by this enzyme (e.g., paclitaxel, rosiglitazone, and 
repaglinide) (14).  
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1.12. RECENT STUDY ON MONTELUKAST SODIUM 
The first demonstrations of the efficacy of Montelukast in asthma were obtained in the mid-
1990s, when the results of both comparative studies of Montelukast versus placebo and studies 
of the protective effect of Montelukast on bronchoconstriction induced by exercise or other 
nonspecific stimuli were published (29,30). Montelukast improved symptoms, rescue medication 
use and pulmonary function, and reduced the rate of exacerbation and the level of blood 
eosinophils, in mild-to-moderate asthmatics not treated with ICS. Montelukast also protected 
against bronchoconstriction induced by exercise better than long-acting beta2-agonists (LABAs) 
(22). These data led to the introduction of Montelukast into the market at the end of the 1990s. 
At the same time, the efficacy of Montelukast in rhinitis was evaluated in other studies, which 
showed that Montelukast was effective and well tolerated with additional benefits over 
antihistamines, although still less effective than intranasal corticosteroids (31). The following 
studies were conducted in an attempt to determine the place of Montelukast in asthma treatment. 
Nayak A. published an excellent review in Expert Opinion on Pharmacotherapy journal entitled 
“A review of montelukast in the treatment of asthma and allergic rhinitis” (Expert Opinion 
Pharmacotherapy, 2004; 5(3): 679-86) (32). The review gives a description of Montelukast 
sodium (Singulair, Mreck) as a selective and orally-active leukoriene-receptor antagonist 
(LTRA) which inhibites the cysteinyl leukotriene 1 (CysLT 1) receptor. It is one of the effective 
and most tolerated preventative treatments for asthma and allergic rhinitis in adults and children. 
Similar inflammatory response to allergen challenge was found for both upper and lower airway. 
Leukotriene are inflammatory mediator substances that are known as the slow-reacting 
substances of anaphylaxis produced by a number of cell types including mast cells, eosinophils, 
basophils, macrophages, and monocytes. Synthesis of these mediators results from the cleavage 
of arachidonic acid in cell membranes and they exert their biological effects by binding and 
activating specific receptors. This causes a series of events that lead to contraction of the human 
airway smooth muscle, chemotaxis and increased vascular permeability. These effects have led 
to their important role in the diseases of asthma and allergic rhinitis. As these agents lead to the 
production of symptoms in patients that are asthmatic or allergic, the use of LTRAs, particularly 
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Montelukast, may seem appropriate. Clinical trials have shown that Montelukast is effective and 
safe in the patient with such diseases. 
According to a study by Okumu A, DiMaso M, Lobenberg R on “Dynamic dissolution testing 
to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug” 
(Pharma Res. 2008 Dec; 25(12):2778-85) (33). 
A dissolution test method was developed that can predict the oral absorption of Montelukast 
sodium, and to establish an in vitro/in vivo correlation (IVIVC) using computer simulation. 
Using different media Drug solubility was measured. The dissolution behavior of Montelukast 
sodium 10mg film coated tablets was studied using the flow-through cell dissolution method 
following a dynamic pH change protocol, as well as in the USP Apparatus 2. Computer 
simulations were performed using GastroPlus. Biorelevent dissolution media (BDM) was 
prepared using bile salts and lecithin in buffers was used as the dissolution media, as well as the 
USP simulated intestinal fluid (SIF) pH 6.8 and blank FaSSIF pH 6.5. Dissolution tests in the 
USP Apparatus 2 were performed under a constant pH condition, while the pH range used in 
flow-through cells was 2.0-7.5. The in vitro data were used as input functions into GastroPlus to 
simulate the in vivo profiles of the drug. At low pH the solubility of the Montelukast sodium was 
low, but with the increase of pH the solubility also increased. No significant difference in the 
solubility was found in the pH range of 5.0 to 7.5 in blank buffers, but the solubility of the drug 
was higher in biorelevant media compared with the corresponding blank buffers at the same pH. 
Using the flow through cells, the dissolution rate was fast in simulated gastric fluid containing 
0.1% SLS. The dissolution rate slowed down when the medium was changed to FaSSIF pH 6.5 
and increased when the medium was changed to FaSSIF medium at pH 7.5. In the USP 
Apparatus 2, better dissolution was observed in FaSSIF compared with the USP buffers and 
blank FaSSIF with similar pH values. Dissolution was incomplete with less than 10% of the drug 
dissolved in the USP-SIF, and was practically nonexistent in blank FaSSIF . 
A study was performed by Fey C, Thyroff-Friesinger, Jones S. et al on “Bioequivalence of two 
formulations of montelukast sodium 4mg oral granules in healthy adults” (34). The aim of 
the study to compare bioavailability, and characterize the pharmacokinetic profile and safety of 
Sandoz generic Montelukast 4mg oral granules relative to Singular mini (Merck, Sharp & 
Dohem). An open-label, randomized, single-dose, two-treatment, two-period, two-sequence, two 
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way crossover bioequivalence study was performed in healthy male volunteers aged 18-55 years, 
under fasting conditions. The duration of the clinical part of the trial was almost 11 days. The 
plasma level of Montelukast was quantified using a validated liquid chromatography tandem 
mass spectrometry method, and pharmacokinetic parameters calculated from the drug 
concentration –time profile using a non-compartmental model. A total of 40 subjects completed 
both study periods. The ratio test/reference of geometric least squares means was  calculated for 
both study formulations of Montelukast for the In-transformed pharmacokinetic parameters; the 
90% confidence intervals (CIs) were within the pre-defined limits of 80.00-125.00%: 92.2% 
(90% Cl:87.42-97.30%) for Cmax, 98.1% (90% Cl:94.49-101.81%) for AUC(0-t) and 97.6% 
(90%Cl:94.14-101.27%) for AUC(0-∞). Two study subjects each reported one mild adverse 
event: dyspepsia (possibly related to study medication) and throat pain (not consider related to 
study medication). Sandoz Montelukast 4mg oral granules are bioequivalent to Singulair 4mg 
mini oral granules, with a similar safety profile. This suggests that these two preparations can be 
considered interchangeable in clinical practice. 
Mclvor A, Kaplan A, Koch C et al carried out a study on “Montelukast as an alternative to 
low-dose inhaled corticosteroids in the management of mild asthma (the SIMPLE trial): An 
open-label effectiveness trialˮ (Can Respir J. 2009 May-Jan; 16 (Suppl A): 11A-16A (35). 
The objective of the study was to evaluate the effectiveness of Montelukast as monotherapy for 
patient with mild asthma who remains uncontrolled or unsatisfied while on inhaled corticosteroid 
(ICS) monotherapy. 
The design of the study included a multicenter, open-label study. Patients (six years of age or 
older) had ICS therapy discontinued and were treated with orally administered Montelukast once 
daily for six weeks. The primary outcome measure was the rate at which asthma symptom 
control was achieved or maintained after six weeks of treatment. The secondary outcome 
measures were to compare compliance and physician satisfaction, and to further assess the safety 
and tolerability of montelukast. 
Of the 534 patients enrolled, 481 (90.1%) completed the study. Mean (±SD) age was 27.8±19.0 
years. The number of patients with uncontrolled symptoms decreased from 455 (85.2%) at 
baseline to 143 (26.8%) at week 6 (P<0.001), and mean Asthma Control Questionnaire score 
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decreased from 1.4±0.8 to 0.6±0.6 (P<0.001), representing a clinically significant improvement. 
Of the 79 patients with controlled asthma symptoms at baseline, 73.4% maintained asthma 
control at week 6. Compliance to asthma therapy increased from 41% at baseline for ICS to 88% 
at week 6 for Montelukast (P<0.001). Physician satisfaction with treatment increased from 43% 
to 85% (P<0.001) and patient satisfaction increased from 45% at baseline to 94% at week 6. No 
serious adverse effects were reported over the course of study. From the study they observed that 
Montelukast is an effective ad well-tolerated alternative to ICS in patients with mild asthma who 
are uncontrolled or unsatisfied with low-dose ICS therapy. 
A research work was performed by Takeda K, Shiraishi Y, Matsubara S in the year 2010 on 
“Effects of combination therapy with montelukast and carbocysteine in allergen-induced 
airway hyperresponsiveness and airway inflammation” (36). According to them the selective 
cysteinyl LT receptor 1 antagonist, Montelukast, has been widely used in the treatment of asthma 
and has been shown to be effective through the suppression of Th2 cytokine production and 
airway inflammation.  
S-carbocystine was originally introduced as a muciregulator to decrease mucus viscosity and 
improve mucus clearance, and has been used in the treatment of mucus-associated respiratory 
diseases such as chronic obstructive pulmonary disease for more than 30 years. Further S-
carbocysteine has been shown to have an anti-oxidant effect and inhibitory activity on neutrophil 
chemotaxis. S-carbocysteine treatment reduced AHR (airway hyperresponsiveness) and 
inflammatory cell infiltration into the airways through increasing levels of Th1 cytokines. 
Thus, S-carbocysteine and Montelukast have distinct activities in reducing allergen-induced 
airway inflammation and airway dysfunction. There are limitations with the use of either drug 
alone. Montelukast given alone is not enough to reduce use of inhaled corticosteroids in 
chilshood asthma patients and S-carbocysteine does not have clear evidence of efficacy in 
asthma. In this study, the potency of a combination of S-carbocysteine and Montelukast in 
allergen-induced AHR (airway hyperresponsiveness) and airway inflammation was examined in 
a secondary allergen challenge model where airway allergic inflammation was established before 
drug treatment was initiated in an attempt to more closely model the clinical situation. 
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The finding of the research work was the combination of S-carbocysteine and Montelukast 
demonstrated additive effects in the prevention of a allergen-induced airway inflammation and 
AHR (airway hyperresponsiveness) through complementary activities and as such, this 
combination may be beneficial in the treatment of asthmatics, especially those refractory to 
treatment with either drug alone and where the use of corticosteroids must be reduced. 
Kose E, Beytur A, Dogan Z et al performed a study on “The effects of montelukast against 
amikacin-induced acute renal damage” (Eur Rev Med Pharmacol Sci 2012 Apr; 16(4):503-11) 
(37). 
The objective of the study was to determine the therapeutic and protective effects of Montelukast 
against amikacin-induced acute renal damage. 
35 Wister albino female rats were divided into 5 groups as follows: 
Group I: Control 
Group II: Control+Montelukast 
Group III: Amikacin 
Group IV: Amikacin+Montelukast 
Group V: Montelukast+Amikacin 
At the end of the experiment, the kidney tissues and the blood of rats were collected. 
Malondialdehyde (MDA), myeloperoxidase (MPO), and reduced glutathione (GSH) levels were 
determined for kidney tissues. Blood urea nitrogen (BUN), creatinine (Cr), TNF-alpha and IL-
1beta levels were assessed in the serum. In addition the kidney tissues were examined 
histologically. 
The MDA, MPO, BUN, and Cr levels of group III significantly increased when compared to 
groups I and II. These parameters of group IV decreased when compared to group III. In 
addition, GSH levels significantly increased when compared to the first three groups. MDA, 
BUN and Cr levels of group V did not reach significant level in comparison with the control 
group. The most significant histological damage was observed in the group III followed by the 
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groups IV and V. Immunohistochemically, group III showed a significantly increased apoptotic 
staining. In group IV, it was observed that Montelukast treatment reduced the expression of 
apoptotic cells.  
A study was conducted by Hardwick C, White D, Morris E et al on “Montelukast in the 
treatment of HIV associated immune reconstitution diseases” (Sex Transm Infact. Dec 2006; 
82(6): 513-514) (38). 
According to the study the pathogenesis of immune reconstitution diseases (IRD) is not well 
understood and it can be difficult to manage. Leukotrienes exert proinflammatory effects, have 
an important role in the innate immune response, and are relatively deficient in HIV infection. 
They report a series of three patients with severe HIV associated IRD, who obtained clinically 
dramatic responses to treatment with montelukast. The first case is of IRD to secondary syphilis 
and resolve on restarting. Montelukast should be consider in HIV associated IRD as an 
alternative to steroids and where these are not effective. Leukotriene overactivity may be 
implicated in IRD. 
Naser A, Natour S, Qaddomi A et al researched on “Formulation and in vitro and in vivo 
evaluation of film-coated montulukast sodium tablets using Opadry yellow 20A82938 on an 
industrial scale” (Drug Des Devel Ther.2013; 7: 83-91). (39) The purpose of the study was to 
formulate stable film-coated montelukast sodium (MS) tablets using Opadry yellow 20A82938 
and to evaluate their in vitro and in vivo release profile. 
Montelukast sodium core tablets were manufactured using a direct compression method. Opadry 
yellow 20A82938 aqueous coating dispersion was used as the film-coating material. Dissolution 
of the film-coated tablets was tested in 900 ml of 0.5% sodium lauryl sulfate solution and the 
bioequivalence of the tablets was tested by comparing them with a reference formulation-
Singulair tablets. In vitro-in vivo correlation was evaluated. The stability of the obtained film-
coated tablets was evaluated according to International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines. 
The efficiency of the film coating was determined by subjecting the coated tablets to gastric pH 
and drug release was analyzed using high-performance liquid chromatography. The coated 
tablets had no obvious defects. Montelukast sodium release met the study criterion of not less 
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than 80% dissolved after 30 minutes in 0.5% sodium lauryl sulfate solution. Statistical 
comparison of the main pharmacokinetic parameters clearly indicated no significant difference 
between test and reference in any of the calculated pharmacokinetic parameters. Level A 
correlation between in vitro drug release and in vivo absorption was found to be satisfactory. 
The findings suggest that aqueous film coating with Opadry yellow 20A82938 is an easy, 
reproducible and economical approach for preparing stable montelukast sodium film-coated 
tablets without affecting the drug-release characteristics. 
Ahmed B, Abdalla A. conducted a research on “Comparison of FT-NIR Transmission and 
HPLC to Assay Montelukast in Its Pharmaceutical Tablets” (American Journal of Analytical 
Chemistry, 2011, 2, 885-891) (40). They use near-infrared spectroscopy (NIRS) as an analytical 
technique. The goal of this study is to show the capacity of this new technique to assay the active 
ingredient in low-dosage tablets. NIR spectroscopy is a rapid, non-destructive technique and 
does not need any sample preparation. A prediction model was built by using a partial least 
square regression fit method. The NIR assay was performed by transmission. The results 
obtained by NIR spectroscopy were compared with the conventional HPLC method for 
Montelukast tablets produced by Sigma pharmaceutical corp. The study showed that 
Montelukast tablets can be individually analyzed by NIR with high accuracy. It was shown that 
the variability of this new technique is less important than that of the conventional method which 
is the HPLC with UV detection. 
 
According to a study on “A simple spectrophotometric assay of Montelukast in 
Pharmaceutical formulations” (J. Chem. Pharm. Res., 2011, 3(6):23-27) by Srihari G, 
Nagaraja K, Rami N (41), a simple and sensitive spectrophotometric method was developed by 
them for the estimation of Montelukast by formation of ion pair complex with wool fast blue. 
The ion pair complex is formed by the interaction of drug with wool fast blue. Wool fast blue is 
insoluble in water and soluble in chloroform. The organic layer is extracted from chloroform and 
the absorbance of organic layer is measured at 585 nm against chloroform blank. Montelukast 
and wool fast blue was treated with chloroform in the pH 1.5 to form ion pair complex. The 
complex is extracted from the chloroform layer. The absorption spectral analysis shows that the 
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maximum of absorbance of Montelukast was found to be 585 nm. The absorbance of blue 
chloroform layer is measured at 585 nm against reagent blank. 
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2. MATERIALS AND METHODS  
2.1. MATERIALS 
The materials used throughout the study are listed in Table 2. 
Serial no. 
 
Materials 
 
01. Tablets of ten different Bangladeshi pharmaceutical company 
02. Syringe 
03. Filter paper 
04. Beaker 
05. Volumetric flask 
06. Measuring cylinder 
07. Filter funnel 
08. Mortar and pestle 
 
Table-2. List of Materials Used for Study  
 
 
2.2. REAGENTS 
 
2.2.1. Reagents for disintegration test 
The reagents used for disintegration test is shown in Table 3. 
  
Serial No. 
 
 
Reagents 
01. Distilled water 
 
Table-3.  Reagent for Disintegration Test  
 
2.2.2. Reagents for dissolution test 
The reagents used for dissolution test is shown in Table 4. 
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Serial No. 
 
 
Reagents 
01. Acetonitrile 
02. Distilled water 
03. Glacial acetic acid 
04. Sodium lauryl sulfate 
05. Active drug(standard) 
06. Methanol 
07. Ammonium acetate 
 
Table-4.  List of Reagents for Dissolution Test 
 
 
2.3. EQUIPMENTS  
The equipments used throughout the study are listed in Table 5. 
 
Name of the Equipment 
 
 
Model 
 
Manufacturer 
 
Country of Origin 
01. Analytical Balance  
 
ATX Series 
Max Cap: 210g, 
Readability: 
0.001g 
OHAUS Corp. pine 
Brook, 
USA 
02. Hardness tester Monsanto 
Hardness Tester. 
Model: EH-01. 
(Braking force 
tester USP-12) 
Electrolab. India 
03. Friabilator.  EF- 
FRIABILATOR 
Electrolab. India 
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Name of the Equipment 
 
 
Model 
 
Manufacturer 
 
Country of Origin 
04. Disintegration 
machine 
ED-2L Electrolab. India 
05. Dissolution machine UDT-804-8 LOGAN USA 
06. pH meter Seven compact 
S220-K 
Mettler-Toledo Switzerland 
07. HPLC  SPD-M20A, 
(Prominence 
Diode array 
detector). 
DGU-20A5R 
(degassing unit). 
LC-20AT, 
(prominence 
Liquid 
chromatography) 
SIL-20AHT, 
(prominence 
auto sampler). 
CTO-10ASVP, 
(column oven). 
SHIMADZU Japan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table-5. List of Equipments Used for Study 
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2.4. METHODS 
Samples of Montelukast sodium tablets from total ten different companies were taken from top 
ranked to middle and lower ranked pharmaceutical companies by considering their popularity 
and in terms of sales in the local market. The leading pharmaceutical companies have been 
represented as A-E respectively, the middle ranked companies are designated by F, G, H and the 
low ranked companies as I and J respectively. All the companies were from Bangladeshi 
pharmaceutical companies and the following quality control tests were performed. 
2.4.1. Weight variation test 
Weight variation test is performed to determine the uniformity of the tablet weights. 
The weight of the tablet is the quantity of tablet granules that contain the labeled amount of 
therapeutic ingredient. After the tablets are prepared the weights are checked regularly to ensure 
the acclaimed weight of the tablet. 
20 tablets were taken and weighed properly. Then the average weight was determined which was 
the standard weight of an individual tablet. Weight of each tablet was taken separately and 
observed whether the individual tablets were within the range or not. 
2.4.2. Hardness test 
Hardness test is done to find out the hardness of tablets by using hardness tester. 
Too soft tablets can disintegrate while transportation. Too hard tablets could be a problem too as 
it can damage the teeth and will take more time to disintegrate within the body. An acceptable 
hardness is required and tablet strength testing is necessary for both research and development of 
new formulations and for quality control of the tablet formulation. 
First of all the sliding scale of the hardness tester was adjusted by bringing it to zero. Then the 
tablet was placed vertically between the two jaws of the hardness tester. Force was applied by 
rotating the screw thread and spring of the tester until the tablet fractured. The reading form 
hardness tester was taken and was displayed in kilogram/cm2 (kg/cm2). The process was repeated 
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for about ten times with ten different tablets of the same variety. Then the average hardness of 
the tablet was calculated. 
2.4.3. Friability test 
Friability test is done to determine how well tablets will stand up to coating, packaging, shipping 
and other mechanical and processing conditions. 
Friability is the measurement of the tendency of a tablet to crack, crumble or break when 
compressed. This tendency is usually confined to uncoated tablet and surfaces during handling or 
subsequent storage. 
Weight of 10 tablets was taken and considered as initial weight and then they were placed in the 
section 1 of drum of the friability tester and rotated at 25 rpm for 4 minutes and the count was set 
to 100. Then the tablets were reweighed and considered as a final weight. Percentage of loss was 
counted. According to USP, percentage loss of weight should not be more than 1%. 
% loss= (Initial weight-Final weight)/Initial weight×100 
2.4.4. Disintegration test 
The objective of disintegration test is to determine whether tablets or capsules disintegrate within 
the prescribed time when placed in a liquid medium in the experimental conditions. 
First of all the disintegration tester was assembled. 600ml of distilled water was taken in each 
1000ml beaker. The temperature was maintained at 37°C. In each of the 6 tubes one tablet was 
placed. The switch button was turned on and the time taken for the tablet to disintegrate was 
noted down. 
Disintegration is considered to be achieved when there is: 
¾ No residues remain on the screen, or 
¾ If there is a residue, it consists of a soft mass having no palpably firm, unmoistened core, 
or 
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¾ Only fragments of coating (tablets) or only fragments of shell may adhere to the lower 
surface of the disc. 
2.4.5. In vitro Dissolution test 
Dissolution test is an in vitro technique of great importance in formulation and development of 
pharmaceutical dosage forms as it can be used to measure the percentage of drug release as a 
function of time which reflects either reproducibility of the product manufacturing process and 
can predict in certain cases, in vivo drug release. 
2.4.5.1. Preparation of ammonium acetate buffer 
3.85gm ammonium acetate was taken into 1000ml of distilled water. Then pH was adjusted to 
3.5 using glacial acetic acid. 
2.4.5.2. Preparation of 0.5% sodium lauryl sulfate solution (dissolution medium) 
This solution served as a dissolution medium. For each liter of distilled water 5g of sodium 
lauryl sulfate was required. Sodium lauryl sulfate was poured slowly into the distilled water 
without shaking. It took some time to completely dissolve and make a clear solution. 
2.4.5.3. Preparation of Stock Solution 
12.5 mg of Montelukast sodium was taken in a 100 ml clean and dry volumetric flask containing 
1 ml of methanol. When the drug is dissolved then dissolution media was added up to the mark 
to make the stock solution of standard (100 µg/ml). 
2.4.5.4. Parameters of the Analytical method for dissolution 
The parameters of the analytical method used for dissolution is summarized in Table 6.  
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Equipment  Shimadzu HPLC Prominence Liquid 
Chromatogram Integrated with PDA Detector  
Column C-18 column 
Mobile phase Ammonium acetate(pH=3.5): methanol=15:85 
Diluting solution Dissolution media 
Temperature Room temperature (RT) 
Flow rate 1.5ml/min 
Monitoring wavelength 254nm 
Injection volume 10 μl 
Retention time  10 minutes (approx). 
 
Table-6.  Parameters of the HPLC Analytical method used for dissolution  
2.4.5.5. Preparation of Calibration curve 
0.8, 0.9,1.0, 1.1 and 1.2 ml of 100 µg/ml of Montelukast sodium solution were taken into 5 
different 10 ml volumetric flasks and dissolution media was added up to the mark to produce 
10.0, 11.25, 12.5, 13.75 and 15 µg/ml Montelukast sodium solutions respectively. The solutions 
were filtered through 0.2µ disk filter and transferred into clean & dry HPLC vials. Then the 
solutions were injected consecutively into the HPLC machine and the chromatograms were 
recorded. 
 
Concentration (µg/ml)  Peak Area 
10.00 123568 
11.25 147752 
12.50 162814 
13.75 174182 
15.00 193305 
 
Table-7. Peak Areas of Various Concentrations of Standard Solutions 
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Calibration Curve of Standard was constructed by plotting Peak Area versus Concentration using 
Microsoft Office Excel 2007 software. The calibration curve is shown in Figure-9 Linearity was 
observed in the concentration range from 10 – 15µg/ml with a correlation coefficient greater than 
0.98. 
 
Figure-9. Standard Calibration curve for Montelukast sodium 
 
2.4.5.6. Dissolution study  
 
900ml of dissolution medium was placed into each vessel and the apparatus was assembled. 
Then the medium was allowed to equilibrate to a temperature of 37±0.5°C. One tablet was 
placed into each vessel, covered and the apparatus was operated at the specified rate. After 30 
minutes, a definite volume of dissolution medium was withdrawn and filtered with 0.45µm filter 
paper. Then this solution was filtered through 0.2µ disk filter and placed into HPLC vials. After 
that, the solutions were injected consecutively into the HPLC machine and the chromatograms were 
recorded. 
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Dissolution media 0.5% SLS solution in distilled water 
Apparatus Dissolution machine 
Starring speed 50rpm 
Time 30 minute   
Temperature  37ᶱC ± 0.5°C 
 
Table-8. Dissolution Specifications of Montelukast tablets  
The peak areas of dissolution sample solutions were substituted in the equation of standard 
calibration curve in order to calculate the concentrations of Montelukast sodium in the sample 
test solutions. 
The equation derived from the standard calibration curve is as follows - 
               y = 13272x – 5579.8    
Where,  
y = Peak area 
x = Concentration in µg/ml 
 
Finally, the percentage release of drug was calculated using the following equation - 
 
% of dissolution of Montelukast sodium = 
 
Conc. of Montelukast sodium in sample (µg/ml) × 900 (ml) × Y × 100 
100000 (µg) × 100 
  
Where, Y = Potency of Montelukast sodium (Working standard) = 99.9 % 
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3.1. RESULTS  
3.1.1. Weight variation test 
The results of weight variation test (in grams) of the ten chosen pharmaceutical companies (A-J) 
of Bangladesh are as follows: 
Sample 
No. 
A B C D E F G H I J 
01. 0.178 0.337 0.170 0.205 0.153 0.277 0.297 0.243 0.185 0.313 
02. 0.178 0.353 0.169 0.207 0.154 0.259 0.290 0.247 0.185 0.310 
03. 0.177 0.353 0.171 0.206 0.149 0.253 0.300 0.245 0.189 0.315 
04. 0.178 0.355 0.173 0.207 0.156 0.256 0.297 0.245 0.184 0.312 
05. 0.175 0.360 0.173 0.207 0.153 0.287 0.299 0.247 0.183 0.312 
06. 0.177 0.353 0.169 0.206 0.158 0.237 0.294 0.243 0.175 0.313 
07. 0.177 0.355 0.168 0.207 0.155 0.246 0.300 0.243 0.189 0.311 
08. 0.175 0.346 0.175 0.208 0.153 0.245 0.299 0.244 0.187 0.314 
09. 0.177 0.350 0.171 0.208 0.157 0.250 0.305 0.245 0.183 0.317 
10. 0.173 0.356 0.173 0.207 0.144 0.262 0.298 0.245 0.182 0.310 
11. 0.173 0.352 0.169 0.209 0.153 0.263 0.301 0.247 0.183 0.317 
12. 0.176 0.350 0.167 0.205 0.157 0.263 0.297 0.244 0.180 0.310 
13. 0.175 0.336 0.168 0.206 0.151 0.260 0.295 0.245 0.188 0.319 
14. 0.175 0.357 0.170 0.209 0.152 0.260 0.304 0.246 0.186 0.311 
15. 0.173 0.356 0.169 0.211 0.151 0.258 0.300 0.250 0.183 0.306 
16. 0.173 0.349 0.173 0.207 0.158 0.255 0.301 0.246 0.187 0.310 
17. 0.177 0.354 0.170 0.205 0.143 0.253 0.296 0.247 0.191 0.312 
18. 0.174 0.358 0.170 0.205 0.152 0.252 0.300 0.247 0.185 0.313 
19. 0.176 0.349 0.171 0.204 0.158 0.252 0.305 0.244 0.186 0.308 
20. 0.173 0.363 0.170 0.209 0.150 0.271 0.305 0.245 0.184 0.311 
Mean± 
SD 
0.17± 
0.01 
0.35± 
0.01 
0.17± 
0.002 
0.2± 
0.001 
0.15± 
0.004 
0.25± 
0.01 
0.3± 
0.003 
0.24± 
0.001 
0.184± 
0.003 
0.31± 
0.003 
 
Table-9. Results of weight variation test  
 
Note : SD=Standard deviation 
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Figure-12. Comparison of Friability test of different companies 
3.1.4. Disintegration test 
The results of disintegration test (in minutes) of the ten chosen pharmaceutical company of 
Bangladesh are as follows: 
Sample 
No. 
A B C D E F G H I J 
01. 6.02 2.17 2.45 0.59 6.12 7.3 6.04 7.25 5.21 5.57 
02. 6.50 2.2 3.8 0.59 7.05 7.5 6.15 7.3 6.25 5.57 
03. 7.27 2.6 3.12 1.14 7.36 9.38 7.0 7.35 9.3 6.5 
04. 8.07 3.15 3.25 1.44 7.56 9.34 7.0 7.44 10.44 6.25 
05. 8.29 4.08 3.25 2.55 8.09 10.37 7.43 7.44 13.5 6.16 
06. 8.36 4.08 4.2 3.11 8.3 10.35 8.21 7.5 14.1 6.4 
Mean± 
SD 
7.40± 
0.9 
3.05± 
0.8 
3.2± 
0.6 
1.57± 
1.04 
7.4± 
0.78 
9.4± 
1.17 
6.97± 
0.8 
7.38± 
0.1 
9.8± 
3.6 
6.1± 
0.41 
 
Table-12. Results of Disintegration test 
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Figure-24. Comparison of dissolution test of different companies 
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3.2. DISCUSSION 
 
3.2.1. Weight variation test 
 
From the results of weight variation test of the ten different companies, it is apparent that the 
range of values is between 0.17±0.01 gm to 0.35±0.01 gm. Most of the leading companies have 
similar values ranging from 0.17±0.01 gm to 0.2±0.01gm except for one company B which 
represents a value of 0.35±0.01 gm. The middle ranked companies (F, G, H) showed weight 
variation results slightly higher than the leading companies ranging from 0.24±0.001 gm to 
0.3±0.003 gm. The lower selling companies (I and J) showed varying results (0.184±0.003 gm 
and 0.31±0.003 gm respectively). Hence, it can be concluded that there was hardly any variation 
in the result of variation test among the leading companies selling Montelukast sodium in 
Bangladesh and the middle and lower ranked companies showed slightly different results. 
3.2.2. Hardness test  
The results of hardness test showed that the leading companies show different values ranging 
from 5.6±1.2 kg/cm2 to 10±1.02 kg/cm2. Company B, C, D showed very similar values. For 
Company E the value was closer to company B, C and D (7.3±1.1 kg/cm2). However, for 
company A the value (5.6±1.2 kg/cm2) differed greatly from the values of the other four 
dominating companies of Bangladesh. On the contrary the middle ranked companies F and G 
showed almost same values of hardness (6.9±1.8 kg/cm2 and 6.7±0.6 kg/cm2) respectively but 
the company H revealed twice the value (12.48±0.6 kg/cm2) compared to company F and G. 
Among the lower ranked companies I and J, company I showed a good value of hardness 
(5.4±0.7 kg/cm2) but company J showed a very high value of hardness (16.57±1.4 kg/cm2) 
indicating that greater force will be required to break the Montelukast tablets of company J that 
may lead to slight higher disintegrating time which is undesirable. Therefore it can be pointed 
out that except for company H and J; the other companies gave acceptable values of hardness. 
3.2.3. Friability test 
 The values of percentage of loss of Montelukast sodium for the ten Bangladeshi companies 
ranges from 0.11 % to 0.3 %. The percentage loss of values for the leading companies A, B and 
E were very similar (0.11% and 0.22%) and that of companies C and D were slightly higher 
compared to company A, B and E (0.3% and 0.28% respectively). The middle ranked companies 
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F, G and H showed similar values (0.27%, 0.23% and 0.28% respectively) as well and these 
values are slightly higher than the values shown by company A, B and E but almost same as 
company C and D. The low-ranked companies I and J demonstrated values as same as that found 
for the top-ranked companies A and E. Hence, it can be concluded there was hardly much 
difference in results of friability test of the ten companies, thus signifying that the tablets 
produced by the different companies of Bangladesh have sufficient mechanical strength to 
withstand the pressure due to processing, storage and shipment. 
3.2.4. Disintegration test 
The time taken for the Montelukast sodium tablets of the leading companies to disintegrate was 
found to be highly variable ranging from 1.57±1.04 minutes to 7.4±0.9 minutes. Company D 
showed the least time taken for disintegration (1.57±1.04 minutes). Company A and E showed 
equal time for disintegration (7.4±0.9 minutes and 7.4±0.78 minutes respectively). Similarly the 
tablets of company B and C has shown close values for disintegration (3.05±0.8 minutes and 
3.2±0.6 minutes). The disintegration time of the middle-ranked companies F, G, H were slightly 
higher compared to the top companies with F taking the highest time for disintegration (9.4±1.17 
minutes), compared to the other companies. The low-ranked companies I and J also 
demonstrated more time for disintegration and gave values that closely resemble that of the 
middle-ranked companies. Therefore, it can be concluded that tablets of company D (one of the 
leading company) has the lowest disintegration time and F (middle-ranked company) company 
and I (low-ranked company) revealed the highest disintegration time, indicating that company D 
has shown the best result in terms of disintegration time. Among the leading companies, 
company B and C has shown acceptable results but company A has shown a result similar to the 
middle and low-ranked company which was not expected.  
3.2.5. Dissolution test 
All the tablets were studied according to British Pharmacopeia and US FDA guidelines for INN 
drugs for in vitro dissolution of Montelukast tablets (42,43). Percentage of drug released in the 
dissolution medium was calculated following the analytical method proposed by Naga et al. (44) 
represented in Table-7. Quantification of the released drug content was performed by calibration 
curve method (45). 
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A simple high performance liquid chromatography method was used to determine the in vitro 
release of ten different brands of Montelukast sodium available in Bangladesh. Montelukast 
sodium was analyzed using Luna 5µ C-18 column (250×4.6mm i.d.). The mobile phase was 
ammonium acetate pH 3.5: methanol (15:85) at flow rate of 1.5ml/min. The retention time was 
approximately 10 minutes. Detection was carried out at 254nm at room temperature. The method 
was found to be linear within the range of 10-15mg/ml. 
The concentration of each of the six samples for each company was calculated using the equation 
derived from the standard curve y=13272x-5579.8 where y denotes the peak area and x denotes 
the concentration (µg/ml). The average value for concentration of Montelukast sodium was 
considered for each pharmaceutical company (A-J) and it was put in the following equation to 
determine the percentage of drug released after 30 minutes. 
% of dissolution of Montelukast sodium = 
 
Conc. of Montelukast sodium in sample (µg/ml) × 900 (ml) × Y × 100 
100000 (µg) × 100 
  
where, Y = Potency of Montelukast sodium (Working standard) = 99.9 % 
 
All the companies have good dissolution profiles showing greater than 90% of release of drug. The 
leading companies A-E showed consistent results for drug release. Company A demonstrated 
slightly lower release of drug (92.1%) compared to other four leading companies (B, C, D and E). 
Company B, C and E showed almost the same results for percentage of drug release whereas 
company D showed a slightly greater value. The middle ranked company F indicated lower drug 
release (90.5%) compared to company G (113.8%), and company H (100.2%) which are companies 
of the same rank. The low-ranked company I showed that there was 95.7% release of drug after 30 
minutes and for company J % release of drug was 114.4%, clearly indicating a marked difference 
between these two companies. Overall, it can be concluded from the dissolution study that all these 
companies manufacturing Montelukast sodium shows acceptable dissolution profile and complies 
with the specifications of British Pharmacopeia. The high values of percentage release of drug for 
company D, company G and company J may be attributed to personal error during running of the 
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experiment or it may be assumed that the companies may have used greater proportion of active 
pharmaceutical ingredient in the dosage form to increase the shelf-life of the product.                                                   
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CONCLUSION  
The quality control parameters of ten different brands of Montelukast tablets available in 
Bangladesh were evaluated and compared to assess the quality of the tablets. Quality control 
tests such as weight variation, friability, hardness as well as disintegration tests were performed. 
In vitro dissolution study was carried out and analyzed by HPLC to determine the percentage 
release of drug after 30 minutes which may reflect in vivo performance of the drug. The weight 
variation test results showed that there was hardly any variation among the leading 
pharmaceutical companies (value ranging 0.17±0.01 gm to 0.2±0.01 gm) except for company B 
(0.35±0.01 gm) and the middle and lower ranked company showed slightly higher results. The 
tablets of all the ten companies showed acceptable values of hardness except for one low-ranked 
company J with a high value of 16.57±1.4kg/cm2. There was a marginal difference in the result 
of the friability test of the all the ten companies (all values less than 1% according to BP 
specification), signifying that the Montelukast tablets produced by the different companies of 
Bangladesh have sufficient mechanical strength to withstand the pressure due to processing, 
storage and shipment. Disintegration times of the tablets of leading companies were found to be 
within 3 minutes indicating a very good result except for company A (7.40±0.9 minutes). 
Company F (middle-ranked company) and company I (low-ranked company) showed the highest 
disintegration times (9.4±1.17 minutes and 9.8±3.6 minutes respectively). Consequently, the 
percentage release of drug for company A, company F and company I are less compared to other 
companies as shown by the dissolution study. Nevertheless, all the companies showed greater 
than 90% dissolution of drug after 30 minutes, thus complying with the specifications of British 
Pharmacopeia and US FDA guidelines for INN drugs. Hence, it can be concluded that the 
Montelukast tablets produced by the pharmaceutical companies in Bangladesh are of consistent 
quality with very little variation among them and complies with the specifications of British 
Pharmacopeia. 
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